Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes.


Journal

Metabolism: clinical and experimental
ISSN: 1532-8600
Titre abrégé: Metabolism
Pays: United States
ID NLM: 0375267

Informations de publication

Date de publication:
02 2020
Historique:
received: 14 09 2019
revised: 30 10 2019
accepted: 26 11 2019
pubmed: 1 12 2019
medline: 28 4 2020
entrez: 1 12 2019
Statut: ppublish

Résumé

Bile acids (BAs) are signaling molecules controlling lipid and glucose metabolism. Since BA alterations are associated with obesity and insulin resistance, plasma BAs have been considered candidates to predict type 2 diabetes (T2D) risk. We aimed to determine (1) the association of BAs with glucose homeostasis parameters and (2) their predictive association with the risk of conversion from prediabetes to new-onset diabetes (NOD) in a prospective cohort study. 205 patients with impaired fasting glucose (IFG) were followed each year during 5 years in the IT-DIAB cohort study. Twenty-one BA species and 7α-hydroxy-4-cholesten-3-one (C4), a marker of BA synthesis, were quantified by LC/MS-MS in plasma from fasted patients at baseline. Correlations between plasma BA species and metabolic parameters at baseline were assessed by Spearman's coefficients and the association between BAs and NOD was determined using Cox proportional-hazards models. Among the analyzed BA species, total hyocholic acid (HCA) and the total HCA/total chenodeoxycholic acid (CDCA) ratio, reflecting hepatic BA 6α-hydroxylation activity, negatively correlated with BMI and HOMA-IR. The total HCA/total CDCA ratio also correlated negatively with HbA Fasting plasma BAs are not useful clinical biomarkers for predicting NOD in patients with IFG. However, an unexpected association between 6α-hydroxylated BAs and glucose parameters was found, suggesting a role for this specific BA pathway in metabolic homeostasis. IT-DIAB study registry number: NCT01218061.

Identifiants

pubmed: 31785259
pii: S0026-0495(19)30257-4
doi: 10.1016/j.metabol.2019.154042
pii:
doi:

Substances chimiques

Bile Acids and Salts 0
Biomarkers 0
Glucose IY9XDZ35W2

Banques de données

ClinicalTrials.gov
['NCT01218061']

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

154042

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Oscar Chávez-Talavera (O)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France.

Matthieu Wargny (M)

L'institut du thorax, Department of Endocrinology, CIC 1413 INSERM, CHU Nantes, Nantes, France; L'institut du thorax, INSERM, CNRS, Univ. Nantes, CHU Nantes, Nantes, France; Clinique des Données, CHU Nantes, Nantes, France.

Matthieu Pichelin (M)

L'institut du thorax, Department of Endocrinology, CIC 1413 INSERM, CHU Nantes, Nantes, France; L'institut du thorax, INSERM, CNRS, Univ. Nantes, CHU Nantes, Nantes, France.

Amandine Descat (A)

Plateau de Spectrométrie de Masse, PSM-GRITA EA 7365, Faculté de Pharmacie, F-59000 Lille, France.

Emmanuelle Vallez (E)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France.

Mostafa Kouach (M)

Plateau de Spectrométrie de Masse, PSM-GRITA EA 7365, Faculté de Pharmacie, F-59000 Lille, France.

Edith Bigot-Corbel (E)

Department of Biochemistry, CHU de Nantes, Nantes, France.

Marielle Joliveau (M)

L'institut du thorax, Department of Endocrinology, CIC 1413 INSERM, CHU Nantes, Nantes, France.

Jean-François Goossens (JF)

Plateau de Spectrométrie de Masse, PSM-GRITA EA 7365, Faculté de Pharmacie, F-59000 Lille, France.

Cédric Le May (C)

L'institut du thorax, INSERM, CNRS, Univ. Nantes, CHU Nantes, Nantes, France.

Samy Hadjadj (S)

L'institut du thorax, Department of Endocrinology, CIC 1413 INSERM, CHU Nantes, Nantes, France; L'institut du thorax, INSERM, CNRS, Univ. Nantes, CHU Nantes, Nantes, France.

Rémy Hanf (R)

Genfit SA, Loos, France.

Anne Tailleux (A)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France.

Bart Staels (B)

Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France.

Bertrand Cariou (B)

L'institut du thorax, Department of Endocrinology, CIC 1413 INSERM, CHU Nantes, Nantes, France; L'institut du thorax, INSERM, CNRS, Univ. Nantes, CHU Nantes, Nantes, France. Electronic address: bertrand.cariou@univ-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH